Thiseffect was found to be strongest for the subgroup of patients with LVEF <50%(i.e., the mildly reduced HF [HFmrEF] subgroup), who comprised approximatelyone-third of the trial population (HR 0.71; 95% CI 0.57–0.88) [18].Empagliflozin also showed a clinical benefit independent of baseline N-terminalpro-B type natriuretic peptide (NT-proBNP) or high-sensitivity cardiac troponin Tlevels [22]. The gene discussed is NPPB; the disease is hydrops fetalis.